Tectonic Therapeutic (TECX) Projected to Post Earnings on Thursday

Key Points

• Tectonic Therapeutic (TECX) will announce its Q2 2025 earnings on August 13th, with analysts expecting a loss of ($0.98) per share.
• The company's stock has seen a price change with a 12-month range between $13.70 and $61.07, currently opening at $22.53.
• Institutional investors have significantly increased their stakes in Tectonic Therapeutic, with notable increases from firms like Jane Street Group LLC (58.7%) and Goldman Sachs Group Inc. (331.1%).

Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Tectonic Therapeutic to post earnings of ($0.98) per share for the quarter.

Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($1.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.09). On average, analysts expect Tectonic Therapeutic to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Tectonic Therapeutic Stock Performance

Tectonic Therapeutic stock traded up $0.39 during midday trading on Friday, reaching $22.31. 369,780 shares of the stock were exchanged, compared to its average volume of 220,560. The company's fifty day moving average is $21.80 and its 200-day moving average is $23.74. The firm has a market cap of $416.53 million, a PE ratio of -5.52 and a beta of 3.27. Tectonic Therapeutic has a 52 week low of $13.70 and a 52 week high of $61.07.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on TECX shares. Raymond James Financial started coverage on shares of Tectonic Therapeutic in a report on Wednesday, June 11th. They set an "outperform" rating and a $76.00 target price on the stock. Mizuho increased their price target on shares of Tectonic Therapeutic from $51.00 to $85.00 and gave the stock an "outperform" rating in a report on Thursday, May 15th. Lifesci Capital assumed coverage on shares of Tectonic Therapeutic in a report on Friday, June 6th. They issued an "outperform" rating and a $87.00 price target on the stock. Wall Street Zen lowered shares of Tectonic Therapeutic from a "hold" rating to a "sell" rating in a report on Saturday, July 26th. Finally, Truist Financial assumed coverage on shares of Tectonic Therapeutic in a report on Monday, July 21st. They issued a "buy" rating and a $64.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $80.33.

Hedge Funds Weigh In On Tectonic Therapeutic

Several institutional investors and hedge funds have recently made changes to their positions in TECX. Millennium Management LLC grew its holdings in shares of Tectonic Therapeutic by 726.4% during the 1st quarter. Millennium Management LLC now owns 237,938 shares of the company's stock valued at $4,214,000 after purchasing an additional 209,145 shares during the last quarter. Geode Capital Management LLC boosted its position in Tectonic Therapeutic by 242.5% during the 2nd quarter. Geode Capital Management LLC now owns 272,257 shares of the company's stock valued at $5,411,000 after buying an additional 192,770 shares during the period. Goldman Sachs Group Inc. boosted its position in Tectonic Therapeutic by 331.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 104,793 shares of the company's stock valued at $1,856,000 after buying an additional 80,483 shares during the period. Finally, Jane Street Group LLC boosted its position in Tectonic Therapeutic by 58.7% during the 1st quarter. Jane Street Group LLC now owns 47,145 shares of the company's stock valued at $835,000 after buying an additional 17,443 shares during the period. Institutional investors own 62.63% of the company's stock.

Tectonic Therapeutic Company Profile

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.